Home > Dermatology > AAD 2018 > What's hot in atopic dermatitis > IL-4/IL-13 inhibition

IL-4/IL-13 inhibition

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
Conference
AAD 2018
Trial
SOLO
IL-4/IL-13 inhibition: key factor in the AD pathogenesis In the pathogenesis of AD, an immune dysfunction with an enhanced Th2 inflammation is as important as the epidermal barrier dysfunction. Dupilumab, a potent blocker of IL4 and IL13, is the first biologic approved for the treatment of AD. Both cytokines are key mediators of TH2 inflammation, but also lower epidermal barrier proteins [16,17]. Dupilumab impacts both the inflammation and the barrier dysfunction in AD, thus targeting two key factors in AD pathogenesis. As Prof. Eric Simpson, of Oregon Health & Science University, pointed out, about 50% of patients in the SOLO trial treated with a monotherapy of dupilumab gained an improvement in the EASI by 75% [18]. The efficacy is even higher when combined with topical steroids: 69% of patients gained an EASI 75 response, as was shown in the CHRONOS trial [19]. The one-year data of the CHRONOS trial have shown that the effect persists ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on